All In Biotech

Drug Trial Radar · NCT00856284

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Dec 3, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,639 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,639

Actual

Start

Mar 2009

Primary completion

Oct 2012

Study completion Oct 2012

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Mar 5, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • AlogliptinDrug

    Alogliptin tablets

  • MetforminDrug

    Metformin tablets

  • GlipizideDrug

    Glipizide tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52Time frame: Baseline and Week 52
  2. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104Time frame: Baseline and Week 104

Locations

261 sites in 32 countries. Site status is shown where the registry gives one.

  • Site not named

    Montgomery, Alabama

  • Site not named

    Muscle Shoals, Alabama

  • Site not named

    Pell City, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Artesia, California

  • Site not named

    Chico, California

  • Site not named

    Los Alamitos, California

  • Site not named

    Mission Viejo, California

  • Site not named

    National City, California

  • Site not named

    Northridge, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Riverside, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Monica, California

  • Site not named

    Tustin, California

  • Site not named

    Arvada, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Ridgefield, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Brooksville, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Opa-locka, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Addison, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Bloomington, Indiana

  • Site not named

    Evansville, Indiana

  • Site not named

    Indianapolis, Indiana

Showing 40 of 261 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.